An2 Therapeutics Inc., of Menlo Park, Calif., raised $12 million in a series A financing led by Mountain Group Partners. Adjuvant Capital and Biorock Ventures. Brii Biosciences Inc., of Beijing, also participated in the round. An2 plans to use the funds to develop its antibacterial compound targeting tuberculosis. The company licensed rights to the unnamed drug in China to Brii, which will be responsible for the development, manufacturing and commercialization in the licensed territory.

Baudax Bio Inc., of Malvern, Pa., with $19 million in funding from former parent company Malvern-based Recro Pharma Inc., launched as an independent, publicly traded company focusing on advancing non-opioid analgesics and other products for the hospital and acute care settings. Its lead program is intravenous meloxicam for managing moderate to severe pain, which has completed phase III testing. Beginning Nov. 22, Baudax will trade on Nasdaq under the ticker BXRX.

Bio-Path Holdings Inc., of Houston, said it entered agreements with several health care-focused institutional investors for the issuance and sale in a registered direct offering of 808,080 shares of its common stock and warrants to purchase up to 606,060 shares of its common stock, at a combined purchase price of $9.90 per share and associated warrant, for aggregate gross proceeds of about $8 million. H.C. Wainwright & Co. is acting as the exclusive placement agent. Bio-Path intends to use the net proceeds for working capital and general corporate purposes. Shares of Bio-Path (NASDAQ:BPTH) closed Thursday at $7.62, down $2.18, or 22%.

Crispr Therapeutics, of Lug, Switzerland, priced its public offering of 4.25 million shares at $64.50, grossing the company $274.1 million. The underwriters have a 30-day option to purchase an additional 637,500 shares. The company plans to use the additional capital for general corporate purposes, including development of its product candidates and expanding its research development programs. Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC are acting as joint book-running managers for the offering. Chardan, Oppenheimer & Co. Inc., BTIG LLC and Roth Capital Partners are acting as co-managers for the offering. The deal is scheduled to close on or about Nov. 25. Shares of Crispr (NASDAQ:CRSP) closed down $8.03, or 11.9%, to $59.39 on Thursday.

Genesis Therapeutics Inc., of South San Francisco, raised $4.1 million in seed funding led by Andreessen Horowitz with Felicis Ventures as a major investor. The company was spun out of work on artificial intelligence (AI) done in Vijay Pande’s lab at Stanford University. Genesis plans to use its AI platform to develop drugs internally as well as in partnership with other companies.

Genprex Inc., of Austin, Texas, raised approximately $1.26 million selling about 3.2 million shares in a registered direct offering at 40 cents per share. The investors will also receive unregistered warrants to purchase up to an equal number of shares. Genprex plans to use the funds for working capital and general corporate purposes. Joseph Gunnar & Co. is acting as the exclusive placement agent for the deal that’s scheduled to close on or about Nov. 25. Shares of Genprex (NASDAQ:GNPX) closed down 4.78 cents, or 13.7%, to 30.22 cents on Thursday.

Immunitas Therapeutics Inc., of Cambridge, Mass., raised $39 million in a series A financing led by Leaps by Bayer and Novartis Venture Fund. Evotec, M Ventures, Alexandria Venture Investments and other institutional investors also participated in the round. Immunitas plans to use the capital to advance its monoclonal antibodies that bind novel immune targets to clinical studies for oncology indications.

Karuna Therapeutics Inc., of Boston, priced its previously announced public offering of 2.6 million shares at $96 per share, grossing the company approximately $250 million. The underwriters have a 30-day option to acquire an additional 390,000 shares. Karuna plans to use the capital to run a phase III study of Karxt as a treatment for schizophrenia, development and expansion of its pipeline and for working capital and other general corporate activities. Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering. Stifel, Nicolaus & Co. Inc. is also acting as a book-running manager. JMP Securities LLC is acting as lead manager. The deal is scheduled to close on Nov. 25. Shares of Karuna (NASDAQ:KRTX) closed down $29.58, or 27%, to $79.36 on Thursday.

Molecular Templates Inc., of Austin, Texas, priced its public offering of 6 million shares of common stock at $8 per share. The company also sold 250 shares of series A convertible preferred stock, which is convertible into 1,000 shares of common stock, at $8,000 per share. The company plans to use the gross proceeds of $50 million to help fund its ongoing phase II studies for MT-3724, its ongoing phase I study of MT-5111 and the rest of its pipeline, as well as for working capital and general corporate purposes. The underwriters have a 30-day option to purchase an additional 900,000 shares of common stock. Cowen and Co. LLC, Barclays Capital Inc. and Stifel, Nicolaus & Co. Inc. are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager. Ladenburg Thalmann is acting as co-manager. The deal is scheduled to close on Nov. 25. Shares of Molecular Templates (NASDAQ:MTEM) closed up $1.82, or 22%, to $10.09 on Thursday.

Onconova Therapeutics Inc., of Newtown, Pa., priced a public offering of 55 million shares, together with accompanying common stock warrants, at a price of 20 cents per share and associated warrant. The offering was led by health care-dedicated funds and included officers and directors of Onconova. Gross proceeds are expected to be $11 million and will be used to fund the development of clinical and preclinical programs, for other research and development activities and for general corporate purposes, which may include capital expenditures and funding working capital needs. H.C. Wainwright & Co. is acting as exclusive placement agent. Shares of Onconova (NASDAQ:ONTX) closed Thursday at 16 cents, down 46%.

Optinose Inc., of Yardley, Pa., priced its public offering of 4.25 million shares at $9.75 per share, netting the company approximately $39 million. Optinose plans to use the proceeds for working capital and general corporate purposes. Certain shareholders also sold 1.25 million shares as part of the public offering. The underwriters have a 30-day option to purchase an additional 825,000 shares. Jefferies LLC, Cowen and Co. LLC and Piper Jaffray & Co. are acting as the joint lead book-running managers for the offering. BMO Capital Markets Corp. is acting as book-running manager. The deal is scheduled to close on or about Nov. 25. Shares of Optinose (NASDAQ:OPTN) closed down $2.01, or 17.6%, to $9.40 on Thursday.

Phio Pharmaceuticals Corp., of Marlborough, Mass., closed its previously announced public offering of 10 million shares at 10 cents per share, grossing the company $1 million. Phio plans to use the proceeds for the development of its immuno-oncology programs, for other research and development activities and for general working capital needs. H.C. Wainwright & Co. acted as exclusive placement agent for the offering.

No Comments